Clinical Trial Update: Lapatinib Plus Trametinib in KRAS Mutant NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results assess the combination of lapatinib and trametinib in KRAS-mutant cancers, including colorectal cancer and non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Lapatinib (Lapatinib)
• Trametinib (trametinib)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED